Our Pricing

What Results Can You Expect From Mounjaro?

Published on: June 03, 2026

Understanding the mounjaro results timeline uk helps set realistic expectations for your weight loss journey. At Cured Pharmacy, our UK prescribers guide patients through what clinical trials reveal about tirzepatide's effects, from initial appetite changes in week one to sustained weight reduction over 72 weeks. Mounjaro is available from £124.99 following a free online consultation with our UK-registered clinical team.

Mounjaro Results Timeline: Week-by-Week Breakdown

Most patients notice appetite suppression within 3-5 days of their first Mounjaro injection, though measurable weight loss typically begins in week 2-4 [1]. This initial period reflects tirzepatide's dual action on GIP and GLP-1 receptors, which regulate satiety signals and slow gastric emptying.

The SURPASS-1 trial demonstrated average weight reductions of 7-9 kg by week 12 on maintenance doses, with progressive loss continuing through week 40 [1]. Your UK prescriber will start you on a lower dose (2.5 mg weekly) and gradually escalate every 4 weeks to minimise gastrointestinal side effects whilst optimising efficacy.

Peak weight loss occurs between weeks 60-72 in clinical trials, with the 15 mg dose producing average reductions of 22.5% total body weight — significantly higher than comparator treatments [2]. Individual results vary based on adherence, baseline BMI, dietary habits, and physical activity levels.

First Month Expectations

During your first 4 weeks on Mounjaro, expect gradual appetite reduction rather than dramatic weight drops. The initial 2.5 mg dose is intentionally conservative to allow your body to adjust to tirzepatide's effects. Most UK patients lose 2-4 kg in this period, though some experience slower initial progress.

Mild nausea, occasional loose stools, and reduced hunger are common as your digestive system adapts. These effects typically diminish by week 3-4. Your Cured Pharmacy prescriber will monitor your tolerance before approving dose escalation to 5 mg at week 5.

Clinical Trial Data: Mounjaro Results Timeline UK Patients Should Know

The SURPASS-3 trial enrolled 1,444 participants with type 2 diabetes and elevated BMI, comparing tirzepatide against insulin degludec over 52 weeks [2]. Patients on 15 mg Mounjaro achieved mean weight loss of 11.2 kg versus 2.3 kg in the insulin group, with 91% of tirzepatide participants losing at least 5% body weight.

More relevant to UK weight management patients, the SURMOUNT-1 trial studied tirzepatide specifically for obesity treatment in adults without diabetes [3]. At 72 weeks, average weight reductions were 15% (5 mg dose), 19.5% (10 mg dose), and 22.5% (15 mg dose) compared to 3.1% with placebo. These results represent intention-to-treat analysis, meaning they include participants who discontinued treatment.

UK regulators at the MHRA licensed Mounjaro for chronic weight management in 2023 based on this robust evidence base. However, individual outcomes depend on maintaining treatment adherence, following dietary guidance, and incorporating physical activity as recommended by your prescriber.

How Fast Does Mounjaro Work UK Compared to Alternatives?

Head-to-head trials show tirzepatide produces faster initial weight loss than semaglutide-based treatments. In the SURPASS-2 study, Mounjaro 15 mg delivered 12.4 kg average reduction at week 40 versus 6.2 kg with semaglutide 1 mg [4]. This reflects tirzepatide's dual receptor mechanism activating both GIP and GLP-1 pathways.

Compared to daily liraglutide injections, Mounjaro offers the convenience of once-weekly dosing with superior efficacy. The STEP trials showed semaglutide (Wegovy) achieving 14.9% average weight loss at 68 weeks [5], whilst tirzepatide reached 22.5% at 72 weeks in comparable populations [3].

Orlistat-based treatments work through a different mechanism—blocking fat absorption rather than regulating appetite hormones—and typically produce 5-10% weight loss over 12 months. Your Cured Pharmacy prescriber will recommend the most appropriate option based on your medical history, BMI, previous treatment responses, and personal preferences.

Choosing Between Injectable Options

If you prioritise maximum weight loss potential and can tolerate weekly injections, Mounjaro represents the most effective licensed option based on current UK trial data. Patients preferring lower upfront costs may consider starting with semaglutide treatments, which still deliver clinically significant results.

Your UK prescriber will assess contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy. All GLP-1 receptor agonists require prescription approval and cannot be purchased without clinical assessment.

Mounjaro Before and After UK: Setting Realistic Expectations

Whilst clinical trials report average outcomes, individual mounjaro results timeline uk experiences vary considerably. A patient starting at 110 kg with 35 BMI might lose 25 kg over 72 weeks on the 15 mg dose, whilst someone at 90 kg with 32 BMI might lose 18 kg over the same period—both achieving approximately 22% reduction.

Factors influencing your personal results include baseline metabolic rate, insulin sensitivity, adherence to prescribed dosing schedule, dietary quality, sleep patterns, stress levels, and physical activity. The medication facilitates weight loss by reducing appetite and slowing digestion, but requires your active participation in healthier eating behaviours.

Photographic before-and-after comparisons shared in patient communities often show dramatic transformations, but these represent best-case scenarios rather than typical outcomes. Your Cured Pharmacy prescriber will help establish personalised goals based on your starting weight, medical conditions, and treatment history.

Maintaining Mounjaro Weight Loss Results Long-Term

The SURMOUNT-4 trial examined what happens when patients stop tirzepatide after achieving weight loss [6]. Participants who discontinued treatment regained approximately 14% of their body weight over 52 weeks, whilst those continuing Mounjaro maintained losses and lost an additional 5.5%.

This data underscores that Mounjaro works as a chronic weight management medication rather than a short-term solution. UK prescribers typically recommend ongoing treatment for patients who achieve at least 5% weight loss in the first 12-16 weeks, as this predicts better long-term outcomes.

Combining Mounjaro with structured lifestyle changes—such as regular physical activity, portion control, and behavioural therapy—improves maintenance of results. Your prescriber may adjust your dose over time based on weight loss plateau, side effect tolerance, and overall treatment response.

When to Expect Weight Loss Plateau

Most patients experience their fastest weight loss between weeks 12-40, with the rate slowing as they approach weeks 60-72. This plateau effect is physiologically normal as your body adjusts to a lower weight and metabolic rate decreases proportionally.

If weight loss stalls before week 40 despite good adherence, your UK prescriber may recommend dose escalation to the next tier (from 10 mg to 12.5 mg or 15 mg). Alternatively, they might investigate other factors such as medication interactions, thyroid function, or unrecognised caloric intake that could impede progress.

Starting Mounjaro: Your UK Prescription Journey at Cured Pharmacy

Mounjaro is a prescription-only medication in the UK, requiring clinical assessment by a registered prescriber before dispensing. At Cured Pharmacy, the process begins with a free online consultation taking under 3 minutes, where you'll provide medical history, current medications, and weight management goals.

Our UK-registered clinical team reviews your submission within 24 hours. If Mounjaro is deemed appropriate and safe for your circumstances, your prescription is issued and dispensed from our GPhC-registered pharmacy (registration 9012511). Pens are delivered in 100% discreet packaging with next-day delivery options available.

Pricing at Cured Pharmacy starts from £135.00 for Mounjaro KwikPens, with transparent costs displayed before you complete your consultation. There are no hidden fees, subscription traps, or surprise charges. Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical services to ensure patient safety and regulatory compliance.

Your prescriber will provide detailed injection technique guidance, dose escalation schedule, and advice on managing potential side effects. Follow-up consultations are available if you experience concerns or wish to discuss dose adjustments as your treatment progresses.

Scientific References

1. Rosenstock, J., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
2. Ludvik, B., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4 [accessed 13 August 2026]
3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
6. Aronne, L. J., et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary and clinical trial outcomes represent average responses in controlled study populations.